Prekallikrein deficiency is a rare hereditary disorder caused by a deficiency of prekallikrein, a precursor of active kallikrein that is involved in the cascade activation of a system of cofactors that play a key role in hemostasis and regulation of inflammatory systems. Prekallikrein, performing its function in the body, promotes the formation of bradykinin, which in turn affects vascular permeability, blood pressure, and pain sensitivity. Possible manifestations of this deficiency may include an increased risk of thrombosis, cardiovascular dysfunction, and various symptoms of blood system dysfunction.
History of the disease and interesting historical facts
The first mentions of prekallikrein deficiency were recorded in the 1970s, when a group of scientists studying plasma protein polymorphisms discovered a relationship between prekallikrein deficiency and the development of thrombophilia. One of the key studies was the work of a group of American hemostasiologists, who found that the presence of a mutation in the KLKB1 gene encoding prekallikrein leads to a decrease in its level in the blood plasma. Interestingly, some patients experienced unexpected reactions to certain drugs, which contributed to further research into this disease and its genetic nature. An increase in the number of registered cases and a deeper understanding of the molecular mechanisms of prekallikrein deficiency led to an awareness of the importance of early diagnosis and appropriate treatment.
Epidemiology
Prekallikrein deficiency is a rare disease. Current estimates place its prevalence at less than 1 case per 1 million population. The highest incidence of the disease can be observed among certain ethnic groups where mutations in the KLKB1 gene are more common. For example, in some populations with limited genetic diversity, the incidence may reach 1 case per 100,000 people. Incomplete or atypical forms of the disease may also complicate statistical assessment, making epidemiological studies essential for a better understanding of this pathology.
Genetic predisposition to this disease
The genetic basis of prekallikrein deficiency is associated with mutations in the KLKB1 gene, located on chromosome 4. To date, more than 30 different mutations of this gene have been described, which can lead to a decrease or absence of prekallikrein synthesis. The most common of these include deletions, point mutations, and insertions, each of which can have different effects on protein levels and functionality. Disease manifestations can vary from mild thrombophilic conditions to serious vascular catastrophes, which necessitates genetic screening to identify high risks in predisposed individuals.
Risk factors for the development of this disease
Risk factors that contribute to the development of prekallikrein deficiency include:
- Hereditary predisposition - the presence of a family history of diseases associated with hemostasis disorders.
- Ethnicity - Some ethnic groups have a higher risk of developing deficiency.
- Age - manifestations of the disease may vary depending on the age of the patient.
- Hormonal changes - some studies indicate a link between hormone levels and the state of the hemostasis system.
Diagnosis of this disease
Diagnosis of prekallikrein deficiency begins with consideration of clinical symptoms, which may include:
- Thrombosis and thrombophilia, manifested in the form of venous thrombosis.
- Systemic inflammatory reactions.
- Disorders of the cardiovascular system.
Laboratory tests required for diagnosis include:
- Blood test for prekallikrein and kallikrein levels.
- Tests for the activity of the hemostasis system.
Radiological examinations may help to identify thrombus formation. Possible methods include venous ultrasound and angiography. Differential diagnosis requires exclusion of other causes of thrombophilia, such as protein C and S, antithrombin III, and other inherited thrombophilic disorders.
Treatment
Treatment of prekallikrein deficiency is aimed at restoring normal hemostasis and preventing thrombus formation. It may include the following approaches:
- General treatment is the use of anticoagulants to control the blood.
- Pharmacological treatment includes the use of direct anticoagulants or low molecular weight heparins.
- Surgical treatment - if blood clots occur, surgery may be required to remove the clots.
- Other types of treatment include the selection of an individual physical activity program and the use of massage techniques.
List of medications used to treat this disease
The main drugs used to treat and prevent thrombosis in prekallikrein deficiency include:
- Heparin and its derivatives.
- Warfarin and other indirect anticoagulants.
- New generation direct anticoagulants such as rivaroxaban and apixaban.
- Diuretics and drugs that affect hormone levels may be used to manage symptoms.
Disease monitoring
Monitoring of the condition of patients with prekallikrein deficiency consists of regular control examinations:
- Periodic monitoring of plasma prekallikrein and kallikrein levels.
- Quality control of hemostasis through coagulograms.
The prognosis for patients with this condition varies, but with adequate therapy and adherence to doctors' recommendations, most patients can lead an active lifestyle with minimal complications. Complications may include cases of blood clots, which require constant monitoring.
Age-related features of the disease
Prekallikrein deficiency may manifest itself at different ages. In newborns and children, the disease may usually not manifest itself overtly, but the risk of thrombosis may increase with age. In adult patients, symptoms may range from moderate to severe thrombophilic events. In the elderly, combinations with other comorbidities are more common, increasing the risk of complications.
Questions and Answers
- What is prekallikrein deficiency? Prekallikrein deficiency is a rare inherited disorder associated with a deficiency of prekallikrein, leading to hemostasis disorders and an increased risk of thrombosis.
- What are the main symptoms of this disease? The main symptoms include thrombosis, systemic inflammatory reactions and vascular dysfunction.
- How is prekallikrein deficiency diagnosed? Diagnostics include blood tests for prekallikrein levels, a coagulogram, and radiological studies to detect thrombus formation.
- How is this disease treated? Treatment includes anticoagulant therapy, procedural interventions, and individualized thromboembolism management.
- What is the prognosis for prekallikrein deficiency? The prognosis can be favorable with timely monitoring and adequate therapy; complications may occur, but are usually controllable.
